The IMID Forum

The Immune-Mediated Inflammatory Disease Forum
  • 4,9 (8)
  • EDUCAÇÃO
  • QUINZENAL

Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.

  1. ACR 2025 Preview Podcast

    HÁ 1 DIA

    ACR 2025 Preview Podcast

    Join Professors Peter Nash, Janet Pope and Atul Deodhar as they preview what they are most looking forward to this ACR, introducing some of the top chosen abstracts and posters in RA, AxSpA and PsA so that you can better plan your time at what will be a busy and exciting congress. #ACR2025

    23min
  2. Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies

    9 DE OUT.

    Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies

    Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.

    19min
  3. Author Interview: Doctor David Kellner, September 2025

    2 DE OUT.

    Author Interview: Doctor David Kellner, September 2025

    Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor David Kellner, an IGNITE-MSCR Fellow of the Division of Rheumatology, from UCLA Medical Centre, LA, USA, as they discuss his recent review ‘Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis’.

    23min
  4. Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

    25 DE SET.

    Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

    Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he highlights two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.

    9min
  5. Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

    18 DE SET.

    Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

    Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the effectiveness of ixekizumab in real-world patients with axSpA and PsA, and the real‑world comparison of clinical effectiveness of UPA, TNF inhibitors or IL‑17 inhibitors in patients with axSpA after switching from an initial TNF inhibitor.

    21min

  6. 4 DE SET.

    Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

    Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month’s discussion covered the ‘Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis’. Read the full paper summary online at www.imidforum.com.

    8min
  7. Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

    28 DE AGO.

    Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

    Join Professor Peter Nash from Griffith University in Brisbane, and Dr Rodrigo Garcia‑Salinas from Hospital Italiano de La Plata in Argentina, as they discuss Dr Garcia-Salinas’ recent publication ‘Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns’.

    29min
  8. Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

    14 DE AGO.

    Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

    Join Professor Peter Nash from the Griffith University in Brisbane, and authors Dr Martin Schaefer from the German Rheumatology Research Center in Berlin, Germany and Professor Anja Strangfeld, the head of epidemiology at the German Rheumatology Research Centre. In this episode they discuss a recent study from the German RABBIT registry, investigating the comparative risk of malignancies in rheumatoid arthritis patients treated with JAK inhibitors versus bDMARDs.

    45min
Ver tudo (373)

Classificações e avaliações

4,9
de 5
8 avaliações

Sobre

Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.

Informações

  • Criado por
    The Immune-Mediated Inflammatory Disease Forum
  • Anos de atividade
    2015 - 2025
  • Episódios
    373
  • Classificação
    Livre
  • Copyright
    © All rights reserved
  • Site do podcast
    The IMID Forum

Você também pode gostar de